Literature DB >> 24057276

Surgical strategy for T2 and T3 gallbladder cancer: is extrahepatic bile duct resection always necessary?

Sae Byeol Choi1, Hyung Joon Han, Wan Bae Kim, Tae Jin Song, Sung Ock Suh, Sang Yong Choi.   

Abstract

PURPOSE: Resection of the extrahepatic bile duct is not performed uniformly in gallbladder cancer. The study investigated the clinical significance of resection of extrahepatic bile duct (EHBD) in T2 and T3 gallbladder cancer.
METHODS: Between 2000 and 2010, 71 T2 or T3 gallbladder cancer patients who underwent R0 resection at Korea University Medical Center were included. Clinicopathological data were reviewed retrospectively. Survival analysis and comparison between EHBD resection and non-resection groups were performed.
RESULTS: The 32 men and 39 women had 49 T2 tumors and 22 T3 tumors. The overall survival rate was 67.8 % at 3 years and 47.2 % at 5 years. In multivariate analysis for overall survival, lymphovascular invasion and lymph node metastasis were significant independent predictors. Comparing the patients according to EHBD resection, the EHBD resection group demonstrated significantly longer hospital stay, longer operative time, more transfusion requirement, more extensive liver resection, and less treatment of neoadjuvant therapy. Significantly higher proportions of perineural invasion and lymph node metastasis were noted in the EHBD resection group. There were no statistically significant differences in survival between the EHBD resection and non-resection groups.
CONCLUSIONS: Resection of extrahepatic bile duct was not always necessary in T2 and T3 cancers. However, the patients who undergo resection of extrahepatic bile duct tended to have more aggressive tumor characteristics and undergo more aggressive surgical approach. To enhance overall survival for the patients with T2 and T3 gallbladder cancers, surgeons should try to perform R0 resection including EHBD resection.

Entities:  

Mesh:

Year:  2013        PMID: 24057276     DOI: 10.1007/s00423-013-1120-3

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  22 in total

1.  Hepatoduodenal ligament invasion by gallbladder carcinoma: histologic patterns and surgical recommendation.

Authors:  Yuji Kaneoka; Akihiro Yamaguchi; Masatoshi Isogai; Tohru Harada; Masahiko Suzuki
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

2.  Clinical significance of extrahepatic bile duct resection for advanced gallbladder cancer.

Authors:  Yoshihiro Sakamoto; Tomoo Kosuge; Kazuaki Shimada; Tsuyoshi Sano; Taizo Hibi; Junji Yamamoto; Tadatoshi Takayama; Masatoshi Makuuchi
Journal:  J Surg Oncol       Date:  2006-09-15       Impact factor: 3.454

3.  Appraisal of surgical resection of gallbladder cancer with special reference to lymph node dissection.

Authors:  H Shimada; I Endo; Y Fujii; N Kamiya; H Masunari; O Kunihiro; K Tanaka; K Misuta; S Togo
Journal:  Langenbecks Arch Surg       Date:  2000-12       Impact factor: 3.445

4.  Should the bile duct be preserved or removed in radical surgery for gallbladder cancer?

Authors:  T Kosuge; K Sano; K Shimada; J Yamamoto; S Yamasaki; M Makuuchi
Journal:  Hepatogastroenterology       Date:  1999 Jul-Aug

5.  Clinicopathological study of depth of subserosal invasion in patients with pT2 gallbladder carcinoma.

Authors:  Ryoko Sasaki; Noriyuki Uesugi; Hidenori Itabashi; Tomohiro Fujita; Yuichiro Takeda; Koichi Hoshikawa; Masahiro Takahashi; Osamu Funato; Hiroyuki Nitta; Tamotsu Sugai; Senji Kanno; Kazuyoshi Saito
Journal:  J Surg Oncol       Date:  2005-11-01       Impact factor: 3.454

6.  Hepatic resection in 485 R0 pT2 and pT3 cases of advanced carcinoma of the gallbladder: results of a Japanese Society of Biliary Surgery survey--a multicenter study.

Authors:  Tatsuo Araida; Ryouta Higuchi; Mie Hamano; Yoshihito Kodera; Nobuhiro Takeshita; Takehiro Ota; Tatsuya Yoshikawa; Masakazu Yamamoto; Ken Takasaki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009-02-14

7.  Longterm survival after extended resections in patients with gallbladder cancer.

Authors:  Anu Behari; Sadiq S Sikora; Gajanan D Wagholikar; Ashok Kumar; Rajan Saxena; Vinay K Kapoor
Journal:  J Am Coll Surg       Date:  2003-01       Impact factor: 6.113

8.  Aggressive surgical approach for stage IV gallbladder carcinoma based on Japanese Society of Biliary Surgery classification.

Authors:  Hiroaki Shimizu; Fumio Kimura; Hiroyuki Yoshidome; Masayuki Ohtsuka; Atsushi Kato; Hideaki Yoshitomi; Satoshi Nozawa; Katunori Furukawa; Noboru Mitsuhashi; Dan Takeuchi; Kosuke Suda; Isaku Yoshioka; Masaru Miyazaki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-07-30

9.  Hepatectomy of segment 4a and 5 combined with extra-hepatic bile duct resection for T2 and T3 gallbladder carcinoma.

Authors:  Naohiko Kohya; Kohji Miyazaki
Journal:  J Surg Oncol       Date:  2008-05-01       Impact factor: 3.454

10.  A curative resection improves the postoperative survival rate even in patients with advanced gallbladder carcinoma.

Authors:  Masahiro Kai; Kazuo Chijiiwa; Jiro Ohuchida; Motoaki Nagano; Masahide Hiyoshi; Kazuhiro Kondo
Journal:  J Gastrointest Surg       Date:  2007-08       Impact factor: 3.452

View more
  12 in total

1.  Extra-Hepatic Bile Duct Resection: an Insight in the Management of Gallbladder Cancer.

Authors:  Durgatosh Pandey; Pankaj Kumar Garg; N M L Manjunath; Jyoti Sharma
Journal:  J Gastrointest Cancer       Date:  2015-09

2.  Combined extrahepatic bile duct resection for locally advanced gallbladder carcinoma: does it work?

Authors:  Tsuyoshi Igami; Tomoki Ebata; Yukihiro Yokoyama; Gen Sugawara; Takashi Mizuno; Junpei Yamaguchi; Yoshie Shimoyama; Masato Nagino
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

Review 3.  Clinical characteristics of incidental or unsuspected gallbladder cancers diagnosed during or after cholecystectomy: a systematic review and meta-analysis.

Authors:  Kui Sun Choi; Sae Byeol Choi; Pyoungjae Park; Wan Bae Kim; Sang Yong Choi
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

4.  Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer.

Authors:  Faiz Gani; Stefan Buettner; Georgios A Margonis; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2016-05-20       Impact factor: 3.454

5.  Hepatectomy of segment 4b and 5 with extrahepatic bile duct resection for pT2 gallbladder carcinoma is valid: a single-institution result.

Authors:  Shunsuke Onoe; Yuji Kaneoka; Atsuyuki Maeda; Yuichi Takayama; Yasuyuki Fukami; Masatoshi Isogai
Journal:  Updates Surg       Date:  2015-08-19

Review 6.  To Resect or Not to Resect Extrahepatic Bile Duct in Gallbladder Cancer?

Authors:  Paschalis Gavriilidis; Alan Askari; Daniel Azoulay
Journal:  J Clin Med Res       Date:  2016-12-31

7.  Laparoscopic approach to suspected T1 and T2 gallbladder carcinoma.

Authors:  Yusuke Ome; Kazuki Hashida; Mitsuru Yokota; Yoshio Nagahisa; Michio Okabe; Kazuyuki Kawamoto
Journal:  World J Gastroenterol       Date:  2017-04-14       Impact factor: 5.742

8.  Role of common bile duct resection in T2 and T3 gallbladder cancer patients.

Authors:  Jin Hong Lim; Jae Uk Chong; Sung Hoon Kim; Seung Woo Park; Jin Sub Choi; Woo Jung Lee; Kyung Sik Kim
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2018-02-26

9.  Long-term survival of a recurrent gallbladder carcinoma patient with lymph node and peritoneal metastases after multidisciplinary treatments: a case report.

Authors:  Koichi Tomita; Kiminori Takano; Motohide Shimazu; Masaaki Okihara; Toru Sano; Naokazu Chiba; Shigeyuki Kawachi
Journal:  Surg Case Rep       Date:  2016-02-11

10.  Clinicopathological Differences in T2 Gallbladder Cancer According to Tumor Location.

Authors:  Wan-Joon Kim; Tae-Wan Lim; Pyoung-Jae Park; Sae-Byeol Choi; Wan-Bae Kim
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.